Resultats globals: 4 registres trobats en 0.03 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
10 p, 1.7 MB Epidemiology of atopic dermatitis in adults : Results from an international survey / Barbarot, Sebastien (CHU Nantes) ; Auziere, S. (Kantar Health) ; Gadkari, A. (Regeneron) ; Girolomoni, G. (University of Verona) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Simpson, E.L. (Oregon Health & Science University) ; Margolis, D.J. (University of Pennsylvania Perelman School of Medicine) ; de Bruin-Weller, Marjolein (University Medical Center Utrecht) ; Eckert, L. (Sanofi) ; Universitat Autònoma de Barcelona
There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. [...]
2018 - 10.1111/all.13401
Allergy, Vol. 73 Núm. 6 (june 2018) , p. 1284-1293  
2.
10 p, 1.5 MB Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 / Cork, M.J. (University of Sheffield Medical School) ; Eckert, L. (Sanofi) ; Simpson, E.L. (Oregon Health & Science University) ; Armstrong, A. (Keck School of Medicine at USC. University of Southern California) ; Barbarot, Sebastien (CHU Hôtel-Dieu) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Girolomoni, G. (University of Verona) ; de Bruin-Weller, Marjolein (University Medical Center Utrecht) ; Wollenberg, A. (Klinikum der Universität München) ; Kataoka, Y. (Osaka Habikino Medical Center) ; Remitz, A. (Helsinki University Central Hospital) ; Beissert, Stefan (Technische Universität Dresden) ; Mastey, V. (Regeneron Pharmaceuticals Inc.) ; Ardeleanu, Marius (Regeneron Pharmaceuticals Inc.) ; Chen, Z. (Regeneron Pharmaceuticals Inc.) ; Gadkari, A. (Regeneron Pharmaceuticals Inc.) ; Chao, J. (Regeneron Pharmaceuticals Inc.) ; Universitat Autònoma de Barcelona
Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. [...]
2020 - 10.1080/09546634.2019.1612836
Journal of Dermatological Treatment, Vol. 31 Núm. 6 (17 2020) , p. 606-614  
3.
13 p, 409.0 KB Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis / Worm, Margitta ; Simpson, Eric L. (Oregon Health & Science University, Portland) ; Thaçi, Diamant (University of Lübeck, Germany) ; Bissonnette, Robert (Innovaderm Research (Montreal, Canadà)) ; Lacour, Jean Philippe (Nice University Hospital (Niça, França)) ; Beissert, Stefan (Technische Universität Dresden, Germany) ; Kawashima, Makoto (Tokyo Women's Medical University, School of Medicine, Tokyo, Japan) ; Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Smith, Catherine H. (King's College London) ; Beck, Lisa (University of Rochester Medical Center, New York) ; Chan, Kuo-Chen (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Chen, Zhen (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Akinlade, Bolanle (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Hultsch, Thomas (Sanofi Genzyme, Cambridge, Massachusetts) ; Staudinger, Heribert (Sanofi, Bridgewater, New Jersey) ; Gadkari, Abhijit (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Eckert, Laurent (Sanofi, Chilly-Mazarin, France) ; Davis, John D. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Rajadhyaksha, Manoj (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Graham, Neil M. H. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Pirozzi, Gianluca (Sanofi, Bridgewater, New Jersey) ; Stahl, Neil (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Yancopoulos, George D. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Ardeleanu, Marius (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ; Universitat Autònoma de Barcelona. Departament de Medicina
The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD). To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. [...]
2019 - 10.1001/jamadermatol.2019.3617
JAMA Dermatology, Vol. 156 (december 2019) , p. 131-143  
4.
11 p, 351.3 KB The patient-reported disease burden in adults with atopic dermatitis : a cross-sectional study in Europe and Canada / de Bruin-Weller, Marjolein (University Medical Center Utrecht) ; Gadkari, Abhijit (Regeneron Pharmaceuticals. Inc) ; Auziere, S. (Kantar - Health Division) ; Simpson, E. L. (Oregon Health and Science University) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Barbarot, Sebastien (Centre Hospitalier Universitaire de Nantes) ; Girolomoni, Giampiero (Universita di Verona) ; Papp, K. (Probity Medical Research, Waterloo) ; Pink, A. E. (St. John's Institute of Dermatology, Guy's and St. Thomas' NHS Foundation Trust and Kings College London) ; Saba, G. (Kantar - Health Division) ; Werfel, T. (Hannover Medical University) ; Eckert, Laurent (Sanofi) ; Universitat Autònoma de Barcelona
Cross-sectional data on patient burden in adults with atopic dermatitis () from real-world clinical practice are limited. This study compared patient-reported burden associated with adult across severity levels from clinical practices in Canada and Europe. [...]
2020 - 10.1111/jdv.16003
Journal of the European Academy of Dermatology and Venereology, Vol. 34 (january 2020) , p. 1026-1036  

Vegeu també: autors amb noms similars
2 Gadkari, Abhijit
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.